首頁 > 市場調查報告書 > 製藥

生物製劑

質粒 DNA 合同製造全球市場研究報告 - 2023-2030 年行業分析、規模、份額、增長、趨勢和預測

市場調查報告書

商品編碼

1267347

質粒 DNA 合同製造全球市場研究報告 - 2023-2030 年行業分析、規模、份額、增長、趨勢和預測

Global Plasmid DNA Contract Manufacturing Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年04月01日 | 出版商:

Value Market Research | 英文 164 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球對質粒 DNA 合同製造市場的需求將從 2022 年的 3.1353 億美元增長到 2030 年的近 15.8161 億美元，預計 2023-2030 年研究期間的複合年增長率將達到 22.42%。

質粒 DNA 合同製造是將質粒 DNA 的製造外包給第三方合同製造商的過程。質粒 DNA 是一種用於各種應用的 DNA，例如基因治療、疫苗開發和研究。與主染色體分離並可在細胞內獨立復制的環狀 DNA 片段。質粒 DNA 的合同製造通常涉及數十至數百克的大規模生產。

市場動態：

基因治療需求的增長增加了對質粒 DNA 的需求，並推動了質粒 DNA 合同製造市場。此外，質粒 DNA 經常用於個性化醫療的開發，因為它可以根據特定患者的需求進行定制。這推動了對質粒 DNA 合同製造的需求。此外，質粒 DNA 製造技術的技術進步實現了高效且具有成本效益的製造，這促進了市場的增長。此外，不斷增長的研究需求正在推動質粒 DNA 合同製造市場的增長。然而，監管要求可能會阻礙市場增長。

研究報告描述了波特的五力模型、市場吸引力分析和價值鏈分析。這些工具可幫助您清楚地了解您的行業結構並評估您在全球範圍內的競爭吸引力。此外，這些工具還可以對全球質粒 DNA 合同製造市場的每個細分市場進行全面評估。質粒 DNA 合同製造行業的增長和趨勢為這項研究提供了一個整體方法。

市場細分：

本部分按國家/地區提供詳細的細分數據，以幫助您確定每種產品/服務的目標受眾和未來商機。

使用

細胞和基因療法
免疫療法
其他

按治療領域

癌症
感染
自身免疫性疾病
心血管疾病
其他

由最終用戶

製藥和生物技術公司
關於研究機構

按地區分析：

本節介紹了區域前景，重點關注北美、歐洲、亞太地區、拉丁美洲、中東和非洲質粒 DNA 合同製造市場當前和未來的需求。此外，我們還關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的綜合概況和全球競爭格局的詳細視圖。質粒 DNA 合同製造市場的主要參與者包括 Charles River Laboratories、VGXI Inc.、PlasmidFactory GmbH &Co.KG、Boehringer Ingelheim、BioCina、TriLink Biotechnologies、Aster PTE.LTD、Thermo Fisher Scientific, Inc.、VIVE biotech、Lonza。本節概述了競爭格局，包括各種戰略發展，例如主要併購、未來能力、合作夥伴關係、財務概覽、合作、新產品開發和新產品發布。

內容

第一章前言

報告內容
- 目的
- 目標受眾
- USP（獨特的銷售建議）及其提供的內容
調查範圍
調查方法
- 市場調研流程
- 市場研究方法

第 2 章執行摘要

市場亮點
全球市場概況

第 3 章質粒 DNA 合同製造 - 行業分析

簡介 - 市場動態
市場驅動力
市場製約因素
機會
行業趨勢
波特的五力分析
市場吸引力分析
- 市場吸引力分析：按應用
- 按治療領域進行市場吸引力分析
- 最終用戶的市場吸引力分析
- 市場吸引力分析：按地區

第四章價值鏈分析

價值鏈分析
原材料分析
- 原材料清單
- 原材料製造商名單
- 主要原材料價格走勢
潛在買家名單
營銷渠道
- 直接營銷
- 間接營銷
- 市場發展趨勢

第 5 章 COVID-19 爆發的影響分析

第 6 章質粒 DNA 合同製造的全球市場分析：按應用

總結：按應用
過去和未來的數據
分析：按應用
細胞和基因療法
免疫療法
其他

第 7 章全球質粒 DNA 合同製造市場分析：按治療領域分類

按治療領域概述
過去和未來的數據
按治療領域分析
癌症
感染
自身免疫性疾病
心血管疾病
其他

第 8 章最終用戶的全球質粒 DNA 合同製造市場銷售分析

最終用戶總結
過去和未來的數據
最終用戶分析
製藥和生物技術公司
關於研究機構

第9章按地區分列的全球質粒DNA合同製造市場銷售分析

按地區進行的銷售前景分析
介紹銷售分析
北美銷售分析
- 概覽、歷史和預測銷售分析
- 北美各部門的銷售分析
- 北美銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史和預測銷售分析
- 按細分市場進行的歐洲銷售分析
- 按國家/地區劃分的歐洲銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 意大利銷售分析
- 俄羅斯銷售分析
- 其他歐洲銷售分析
亞太地區銷售分析
- 概覽、歷史和預測銷售分析
- 亞太地區各部門的銷售分析
- 亞太國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本的銷售分析
- 韓國銷售分析
- 澳大利亞銷售分析
- 其他亞太地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史和預測銷售分析
- 拉丁美洲各部門的銷售分析
- 拉丁美洲國家/地區的銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利的銷售分析
- 其他拉丁美洲銷售分析
中東和非洲銷售分析
- 概覽、歷史和預測銷售分析
- 中東和非洲各細分市場的銷售額分析
- 中東和非洲國家/地區的銷售分析
- 沙特阿拉伯銷售分析
- 阿聯酋銷售分析
- 以色列銷售分析
- 南非銷售分析
- 其他中東和非洲銷售分析

第10章質粒DNA代工企業的競爭狀況

質粒 DNA 合同製造市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他擴展

第11章公司簡介

前 10 名公司的市場份額分析
市場集中度
查爾斯河實驗室
- 公司簡介
- 企業收入
- 產品介紹
- 近期趨勢
VGXI 公司
- 公司簡介
- 企業收入
- 產品介紹
- 近期趨勢
Plasmid Factory GmbH & Co. KG
- 公司簡介
- 企業收入
- 產品介紹
- 近期趨勢
勃林格殷格翰
- 公司簡介
- 企業收入
- 產品介紹
- 近期趨勢
生物中國
- 公司簡介
- 企業收入
- 產品介紹
- 近期趨勢
TriLink 生物技術公司
- 公司簡介
- 企業收入
- 產品介紹
- 近期趨勢
紫苑私人有限公司
- 公司簡介
- 企業收入
- 產品介紹
- 近期趨勢
Thermo Fisher Scientific Inc.
- 公司簡介
- 企業收入
- 產品介紹
- 近期趨勢
VIVE 生物技術公司
- 公司簡介
- 企業收入
- 產品介紹
- 近期趨勢
龍沙
- 公司簡介
- 企業收入
- 產品介紹
- 近期趨勢

注意：在公司簡介、財務細節、近期發展等方面，基於可用信息，私人控股公司可能不包括在內。

簡介目錄圖表

Product Code: VMR112110153

The global demand for Plasmid DNA Contract Manufacturing Market is presumed to reach the market size of nearly USD 1581.61 MN by 2030 from USD 313.53 MN in 2022 with a CAGR of 22.42% under the study period 2023 - 2030.

Plasmid DNA contract manufacturing is the process of outsourcing the production of plasmid DNA to a third-party contract manufacturer. Plasmid DNA is a type of DNA used in various applications, including gene therapy, vaccine development, and research. It is a circular piece of DNA that is separate from the main chromosome and can replicate independently in a cell. Plasmid DNA contract manufacturing involves the production of plasmid DNA on a large scale, typically in the tens to hundreds of grams.

Market Dynamics:

The growing demand for gene therapy increases the need for plasmid DNA, which is driving the market for plasmid DNA contract manufacturing. Moreover, plasmid DNA is often used to develop personalized medicine, as it can be customized to specific patient needs. This is driving the demand for plasmid DNA contract manufacturing. Furthermore, technological advances in the production technology for plasmid DNA have made it more efficient and cost-effective, which has contributed to the market's growth. In addition, the rising demand for research drives the plasmid DNA contract manufacturing market growth. However, the regulatory requirements may impede the market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of plasmid dna contract manufacturing. The growth and trends of plasmid dna contract manufacturing industry provide a holistic approach to this study.

Market Segmentation:

This section of the plasmid dna contract manufacturing market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Application

Cell & Gene Therapy
Immunotherapy
Others

By Therapeutic Area

Cancer
Infectious Diseases
Autoimmune Diseases
Cardiovascular Diseases
Others

By End-User

Pharmaceutical And Biotechnology Companies
Research Institutes

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Plasmid DNA Contract Manufacturing market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the plasmid dna contract manufacturing market include Charles River Laboratories, VGXI Inc., PlasmidFactory GmbH & Co. KG, Boehringer Ingelheim, BioCina, TriLink Biotechnologies, Aster PTE. LTD, Thermo Fisher Scientific, Inc., VIVE biotech, Lonza. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . PLASMID DNA CONTRACT MANUFACTURING - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Application
- 3.7.2 Market Attractiveness Analysis By Therapeutic Area
- 3.7.3 Market Attractiveness Analysis By End-user
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL PLASMID DNA CONTRACT MANUFACTURING MARKET ANALYSIS BY APPLICATION

6.1 Overview by Application
6.2 Historical and Forecast Data
6.3 Analysis by Application
6.4 Cell & Gene Therapy Historic and Forecast Sales by Regions
6.5 Immunotherapy Historic and Forecast Sales by Regions
6.6 Others Historic and Forecast Sales by Regions

7 . GLOBAL PLASMID DNA CONTRACT MANUFACTURING MARKET ANALYSIS BY THERAPEUTIC AREA

7.1 Overview by Therapeutic Area
7.2 Historical and Forecast Data
7.3 Analysis by Therapeutic Area
7.4 Cancer Historic and Forecast Sales by Regions
7.5 Infectious Diseases Historic and Forecast Sales by Regions
7.6 Autoimmune Diseases Historic and Forecast Sales by Regions
7.7 Cardiovascular Diseases Historic and Forecast Sales by Regions
7.8 Others Historic and Forecast Sales by Regions

8 . GLOBAL PLASMID DNA CONTRACT MANUFACTURING MARKET SALES ANALYSIS BY END-USER

8.1 Overview by End-user
8.2 Historical and Forecast Data
8.3 Analysis by End-user
8.4 Pharmaceutical And Biotechnology Companies Historic and Forecast Sales by Regions
8.5 Research Institutes Historic and Forecast Sales by Regions

9 . GLOBAL PLASMID DNA CONTRACT MANUFACTURING MARKET SALES ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook Sales Analysis
9.2. Introduction Sales Analysis
9.3. North America Sales Analysis
- 9.3.1. Overview, Historic and Forecast Sales Analysis
- 9.3.2. North America By Segment Sales Analysis
- 9.3.3. North America By Country Sales Analysis
- 9.3.4. United State Sales Analysis
- 9.3.5. Canada Sales Analysis
- 9.3.6. Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1. Overview, Historic and Forecast Sales Analysis
- 9.4.2. Europe by Segment Sales Analysis
- 9.4.3. Europe by Country Sales Analysis
- 9.4.4. United Kingdom Sales Analysis
- 9.4.5. France Sales Analysis
- 9.4.6. Germany Sales Analysis
- 9.4.7. Italy Sales Analysis
- 9.4.8. Russia Sales Analysis
- 9.4.9. Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1. Overview, Historic and Forecast Sales Analysis
- 9.5.2. Asia Pacific by Segment Sales Analysis
- 9.5.3. Asia Pacific by Country Sales Analysis
- 9.5.4. China Sales Analysis
- 9.5.5. India Sales Analysis
- 9.5.6. Japan Sales Analysis
- 9.5.7. South Korea Sales Analysis
- 9.5.8. Australia Sales Analysis
- 9.5.9. Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1. Overview, Historic and Forecast Sales Analysis
- 9.6.2. Latin America by Segment Sales Analysis
- 9.6.3. Latin America by Country Sales Analysis
- 9.6.4. Brazil Sales Analysis
- 9.6.5. Argentina Sales Analysis
- 9.6.6. Peru Sales Analysis
- 9.6.7. Chile Sales Analysis
- 9.6.8. Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1. Overview, Historic and Forecast Sales Analysis
- 9.7.2. Middle East & Africa by Segment Sales Analysis
- 9.7.3. Middle East & Africa by Country Sales Analysis
- 9.7.4. Saudi Arabia Sales Analysis
- 9.7.5. UAE Sales Analysis
- 9.7.6. Israel Sales Analysis
- 9.7.7. South Africa Sales Analysis
- 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE PLASMID DNA CONTRACT MANUFACTURING COMPANIES

10.1. Plasmid Dna Contract Manufacturing Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11 . COMPANY PROFILES OF PLASMID DNA CONTRACT MANUFACTURING INDUSTRY

11.1. Top 10 Company Share Analysis
11.2. Market Concentration Rate
11.3. Charles River Laboratories
- 11.3.1. Company Overview
- 11.3.2. Company Revenue
- 11.3.3. Products
- 11.3.4. Recent Developments
11.4. VGXI Inc.
- 11.4.1. Company Overview
- 11.4.2. Company Revenue
- 11.4.3. Products
- 11.4.4. Recent Developments
11.5. PlasmidFactory GmbH & Co. KG
- 11.5.1. Company Overview
- 11.5.2. Company Revenue
- 11.5.3. Products
- 11.5.4. Recent Developments
11.6. Boehringer Ingelheim
- 11.6.1. Company Overview
- 11.6.2. Company Revenue
- 11.6.3. Products
- 11.6.4. Recent Developments
11.7. BioCina
- 11.7.1. Company Overview
- 11.7.2. Company Revenue
- 11.7.3. Products
- 11.7.4. Recent Developments
11.8. TriLink Biotechnologies
- 11.8.1. Company Overview
- 11.8.2. Company Revenue
- 11.8.3. Products
- 11.8.4. Recent Developments
11.9. Aster PTE. LTD
- 11.9.1. Company Overview
- 11.9.2. Company Revenue
- 11.9.3. Products
- 11.9.4. Recent Developments
11.10. Thermo Fisher Scientific Inc.
- 11.10.1. Company Overview
- 11.10.2. Company Revenue
- 11.10.3. Products
- 11.10.4. Recent Developments
11.11. VIVE biotech
- 11.11.1. Company Overview
- 11.11.2. Company Revenue
- 11.11.3. Products
- 11.11.4. Recent Developments
11.12. Lonza
- 11.12.1. Company Overview
- 11.12.2. Company Revenue
- 11.12.3. Products
- 11.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

簡介目錄圖表